GlassScriptPhysician profile
Matthew D Rosen
NPI 1992780571
$8,537.49
in general payments reported to CMS, 2019-2025
39 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,197 · 2020: $313 · 2021: $664 · 2022: $1,097 · 2023: $1,701 · 2024: $1,362 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,266.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $985.09 | 2019-2025 | |
| Ge Healthcare | $865.00 | 2019 | |
| Pfizer INC. | $665.97 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $593.59 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $572.70 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $568.19 | 2019-2025 | Watchman Flx, Watchman Access System |
| Amgen INC. | $558.23 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $550.13 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.92 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $337.96 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $266.76 | 2021-2024 | Onpattro |
| Novo Nordisk INC | $218.22 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Esperion Therapeutics, INC. | $214.22 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $176.73 | 2019-2025 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $148.82 | 2019-2024 | Evkeeza |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $147.84 | 2022-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $120.45 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $99.89 | 2021-2023 | Arcalyst |
| Exact Sciences Corporation | $99.07 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $98.03 | 2022-2025 | Corevalve Evolut R |
| Lilly USA, LLC | $96.79 | 2019-2025 | Mounjaro, Zepbound |
| Lexicon Pharmaceuticals, INC. | $92.38 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $89.82 | 2024 | Arcalyst |
| Baxter Healthcare | $83.06 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $61.64 | 2019 | |
| Bardy Diagnostics, INC. | $60.00 | 2019-2020 | |
| Amarin Pharma, INC. | $55.07 | 2019-2020 | |
| Glaxosmithkline, LLC. | $54.65 | 2021-2024 | Arexvy, Shingrix |
| Gilead Sciences, INC. | $40.26 | 2019 | |
| Abiomed | $39.95 | 2024 | Impella |
| Genzyme Corporation | $39.18 | 2021-2022 | |
| Scpharmaceuticals INC. | $34.62 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $28.74 | 2019-2021 | |
| Bridgebio Pharma, INC. | $26.59 | 2025 | Attruby |
| Abbott Laboratories | $26.47 | 2019 | |
| Sanofi Pasteur INC. | $21.19 | 2020 | |
| Lantheus Medical Imaging, INC. | $17.44 | 2024 | |
| Aegerion Pharmaceuticals, INC. | $16.63 | 2019 | |
| Medtronic Vascular, INC. | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.